Science Library · GHRH(1-29) analog

Sermorelin the science.

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH) — the active fragment that retains GHRH’s full ability to signal the pituitary. It has the longest clinical research history of the compounds in this group, having been studied in human GH-axis research and as a diagnostic and investigational agent. The summary below reflects published research.

View the Sermorelin product page →

29 aa

Peptide length

GHRH receptor

Primary target

Clinical history

Evidence stage

GHRH(1-29)

Active fragment

How it works

Mechanism at a glance

Compound

Sermorelin

Action

Activates GHRH receptor

Effect

Stimulates endogenous GH release

Studied in

Human GH-axis studies

Evidence to date

In vitro

Animal

Human

Evidence to date: preclinical plus human clinical studies. Reference summary only.

What it is

Sermorelin is the synthetic GHRH(1-29) peptide — the shortest fragment of growth hormone-releasing hormone that retains full biological activity. Like native GHRH, it binds the pituitary GHRH receptor to stimulate the body’s own production and release of growth hormone, working upstream of GH itself.

Because it activates the endogenous GH axis rather than supplying GH directly, sermorelin has been studied in research on GH regulation, in provocative diagnostic testing of pituitary function, and historically in clinical investigation. The summary here is a scientific reference; sermorelin is supplied as a research material.

The pathway under study: the GHRH receptor

Sermorelin research centers on native GHRH-receptor signaling:

GHRH-receptor activation — binding the pituitary GHRH receptor is studied for how it triggers GH synthesis and release.
Pulsatile, feedback-preserving release — because it acts upstream, GH is released in a pattern that retains the axis’s natural negative feedback.
Pituitary-function testing — sermorelin’s reliable GH response has made it a tool for assessing somatotroph capacity.

What research has explored

Sermorelin has both preclinical and substantial human research:

GH-axis treatment studies (1996). A study in the Journal of Clinical Endocrinology & Metabolism reported that once-daily subcutaneous GHRH(1-29) therapy accelerated growth in children with GH-axis insufficiency.
Radiation-related GH-deficiency research (1997). A study in Clinical Endocrinology examined GHRH treatment in radiation-induced GH deficiency, probing pituitary responsiveness.

This material is supplied for research use only; the summary here is a reference to published findings and is not a therapeutic claim about the product.

Current state of the evidence

Sermorelin (GHRH(1-29)) has a longer clinical research history than most compounds in this catalog, including human studies of the GH axis and pituitary function. Regardless, the material here is supplied strictly as a research material for laboratory investigation, and no therapeutic claim, dosing, or indication applies to it.

Compound Snapshot

At a glance

Sources & References

Peer-reviewed research and database records

J. Clinical Endocrinology & Metabolism / PubMed

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children

1996 · PMID 8772599 · DOI 10.1210/jcem.81.3.8772599 View Source

Clinical Endocrinology / PubMed

Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone

1997 · PMID 9231053 · DOI 10.1046/j.1365-2265.1997.1790998.x View Source

PubChem

Sermorelin compound search

NIH PubChem lookup for molecular identity and structure records. View Source

PubMed

Sermorelin GHRH(1-29) literature search

NCBI PubMed index for primary papers, reviews, and PMID-linked records. View Source

For research use only. Not for human or veterinary use. These products have not been evaluated by the FDA. Nothing on this page is medical advice or a therapeutic claim.

Catalog

Explore Sermorelin.

View product →